Loading ...

TfR-targeted PVA-doxorubicin/albumin-sorafenib core-shell nanomedicine

Based on

1 Articles
2014 Most recent source

Composition

1

PVA-doxorubicin nanoparticles

Type Nano Material
Formula
Role core
2

human serum albumin

HSA
Type Biomolecule
Formula
Role layer
3

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

sorafenib SFN SOR SF
Type Single Compound
Formula C21H16ClF3N4O3
Role loaded material
4

human holo-transferrin

Tf
Type Biomolecule
Formula
Role layer

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
doxorubicin drug release

More information available to subscribers only.

Or, view sample content

Applications

Area Application Nanomaterial Variant Source
medicine/veterinary

More information available to subscribers only.

Or, view sample content

Characterization

Method Nanomaterial Variant Source
atomic force microscopy

More information/entries available to subscribers only.

Or, view sample content

Biological effects

Biological system Test details Nanomaterial Variant Source
human hepatoma PLC/PRF/5 cells

More information/entries available to subscribers only.

Or, view sample content

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
  • 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
  • human serum albumin
  1. qMYAA5KwcNZ6vLfDll1ANmw354LCTq
  2. 6R4D2E1y
Product

TfR-targeted PVA-doxorubicin/albumin-sorafenib core-shell nanomedicine

Size: ~ 110 nm

Medium/Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial